Metraipolis › archive › dc_0d53fa4ff467

Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States — Europe PMC PMID:36763574

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/36763574
DOI: 10.1371/journal.pone.0281365
License (as archived): CC0-1.0
Archived: 2026-10-07T17:34:23.593Z
SHA-256 of the archived text: e0311df2d625cda47c077d0f24a8d1d6be28a37487b18ef65a8c643c1215c03d
Stable URL of this page: https://metraipolis.com/documento/dc_0d53fa4ff467

How to cite

Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States — Europe PMC PMID:36763574 — Europe PMC (en), https://europepmc.org/article/MED/36763574 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_0d53fa4ff467 (Metraipolis archive dc_0d53fa4ff467, sha256 e0311df2d625cda47c077d0f24a8d1d6be28a37487b18ef65a8c643c1215c03d)

BibTeX

@misc{dc0d53fa4ff467,
  title = {Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States — Europe PMC PMID:36763574},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36763574},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_0d53fa4ff467; sha256 e0311df2d625cda47c077d0f24a8d1d6be28a37487b18ef65a8c643c1215c03d},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36763574. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: As diagnostic tests for COVID-19 were broadly deployed under Emergency Use Authorization, there emerged a need to understand the real-world utilization and performance of serological testing across the United States. Methods: Six health systems contributed electronic health records and/or claims data, jointly developed a master protocol, and used it to execute the analysis in parallel. We used descriptive statistics to examine demographic, clinical, and geographic characteristics of serology testing among patients with RNA positive for SARS-CoV-2. Results: Across datasets, we observed 930,669 individuals with positive RNA for SARS-CoV-2. Of these, 35,806 (4%) were serotested within 90 days; 15% of which occurred 30%) in some datasets-limiting our ability to examine differences in serological testing by race. In datasets where race/ethnicity information was available, we observed a greater distribution of White individuals among those serotested; however, the time between RNA and serology tests appeared shorter in Black compared to White individuals. Test manufacturer data was available in half of the datasets contributing to the analysis. Conclusion: Our results inform the underlying context of serotesting during the first year of the COVID-19 pandemic and differences observed between claims and EHR data sources-a critical first step to understanding the real-world accuracy of serological tests. Incomplete reporting of race/ethnicity data and a limited ability to link test manufacturer data, lab results, and clinical data challenge the ability to assess the real-world performance of SARS-CoV-2 tests in different contexts and the overall U.S. response to current and future disease pandemics.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-02-10).
Identificativi: PMID 36763574 · PMCID PMC9916659 · DOI 10.1371/journal.pone.0281365.
Descrittori MeSH principali: COVID-19; SARS-CoV-2.
Pagina: https://europepmc.org/article/MED/36763574 — https://doi.org/10.1371/journal.pone.0281365. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T17:04:36.547Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.